Why the study?
What are the preventive strategies to minimize the risk of bleeding in patients taking nonvitamin K antagonist oral anticoagulants?
What are the preventive strategies to minimize the risk of bleeding in patients taking nonvitamin K antagonist oral anticoagulants?
This review highlights essential preventive strategies, such as dose tailoring and managing modifiable risk factors, to minimize bleeding risks associated with NOAC therapy.
Answers are grounded in this paper and cite their sources.
May guide NOAC selection to balance ICH and GI bleeding risks; leaves open optimal preventive strategies pending prospective trials.
Dabigatran etexilate (DE), rivaroxaban, and apixaban are nonvitamin K antagonist oral anticoagulants (NOACs) that have been compared in clinical trials with existing anticoagulants (warfarin and enoxaparin) in several indications for the prevention and treatment of thrombotic events. All NOACs presented bleeding events despite a careful selection and control of patients. Compared with warfarin, NOACs had a decreased risk of intracranial hemorrhage, and apixaban and DE (110 mg BID) had a decreased risk of major bleeding from any site. Rivaroxaban and DE showed an increased risk of major gastrointestinal bleeding compared with warfarin. Developing strategies to minimize the risk of bleeding is essential, as major bleedings are reported in clinical practice and specific antidotes are currently not available. In this paper, the following preventive approaches are reviewed: improvement of appropriate prescription, identification of modifiable bleeding risk factors, tailoring NOAC's dose, dealing with a missed dose as well as adhesion to switching, bridging and anesthetic procedures.
No takes yet. Share an insight, caveat, or question.
Lessire et al. (2014) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: